Andrea Attanasio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea Attanasio has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Gianluigi Guida
Cardiology University Department, IRCCS Policlinico San Donato , Piazza Edmondo Malan, Milan 20097
3 shared publications - Antonia Camporeale
Multimodality Cardiac Imaging Section, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
2 shared publications - Giampaolo Merlini
Amyloid Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, and University of Pavia
2 shared publications Giandomenico Disabato
Multimodality Cardiac Imaging Section, IRCCS Policlinico San Donato, Via Morandi 30, 20097 San Donato Milanese , Milan , Italy
2 shared publications- Giandomenico Disabato
Cardiology University Department, IRCCS Policlinico San Donato , Piazza Edmondo Malan, Milan 20097
2 shared publications Gianluigi Guida
Cardiology University Department, IRCCS Policlinico San Donato, Via Morandi 30, 20097 San Donato Milanese , Milan , Italy
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Impaired Flow and Physiology in Coronaries With Anomalous Origin From the Opposite Sinus of Valsalva
Background: Anomalous Aortic Origin of a Coronary Artery (AAOCA) high‐risk anatomical features (intramural segment, acute take‐off angle, slit‐like ostium) cause coronary stenosis leading to myocardial infarction. How these features alter coronary physiology remains unclear. Aims: We aimed to evaluate their impact on coronary blood supply using continuous thermodilution. Methods: We prospectively enrolled 51 AAOCA patients undergoing continuous thermodilution. Subjects were classified into an ischemic risk (IR) group (intramural segment, acute angle, oval or slit ostium) or non‐ischemic risk (no‐IR) group. Non‐anomalous coronary arteries served as controls. We measured absolute coronary blood flow (CBF) and microvascular resistance. Results: Subjects (median age 48.4 years) presented mostly with angina, syncope, and arrhythmia. Final analysis included 48 AAOCA cases (31 IR, 17 no‐IR) and 45 controls. The IR group had a median IM length of 9 mm, take‐off angle of 31.9°, and a slit‐like or oval ostium. The no‐IR group had a median angle of 51.5° and an oval or round ostium. At rest, absolute CBF and microvascular resistance showed no significant differences among groups. However, during hyperemia, the IR group had significantly reduced CBF compared to controls (179 vs. 290 mL/min, p = 0.015). The IR group demonstrated higher microvascular resistance at rest (1473 vs. 1150, p = 0.024) and during hyperemia (433 vs. 305, p = 0.012), indicating persistently increased coronary vascular tone. Conclusions: High‐risk anatomical features of AAOCA are associated with altered coronary physiology. An intramural segment, acute take‐off angle, and slit‐like or oval ostium are linked to reduced hyperemic coronary blood flow due to increased microvascular resistance.
- 15 October 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Open AccessImpaired Flow and Physiology in Coronaries With Anomalous Origin From the Opposite Sinus of Valsalva
Background: Anomalous Aortic Origin of a Coronary Artery (AAOCA) high‐risk anatomical features (intramural segment, acute take‐off angle, slit‐like ostium) cause coronary stenosis leading to myocardial infarction. How these features alter coronary physiology remains unclear. Aims: We aimed to evaluate their impact on coronary blood supply using continuous thermodilution. Methods: We prospectively enrolled 51 AAOCA patients undergoing continuous thermodilution. Subjects were classified into an ischemic risk (IR) group (intramural segment, acute angle, oval or slit ostium) or non‐ischemic risk (no‐IR) group. Non‐anomalous coronary arteries served as controls. We measured absolute coronary blood flow (CBF) and microvascular resistance. Results: Subjects (median age 48.4 years) presented mostly with angina, syncope, and arrhythmia. Final analysis included 48 AAOCA cases (31 IR, 17 no‐IR) and 45 controls. The IR group had a median IM length of 9 mm, take‐off angle of 31.9°, and a slit‐like or oval ostium. The no‐IR group had a median angle of 51.5° and an oval or round ostium. At rest, absolute CBF and microvascular resistance showed no significant differences among groups. However, during hyperemia, the IR group had significantly reduced CBF compared to controls (179 vs. 290 mL/min, p = 0.015). The IR group demonstrated higher microvascular resistance at rest (1473 vs. 1150, p = 0.024) and during hyperemia (433 vs. 305, p = 0.012), indicating persistently increased coronary vascular tone. Conclusions: High‐risk anatomical features of AAOCA are associated with altered coronary physiology. An intramural segment, acute take‐off angle, and slit‐like or oval ostium are linked to reduced hyperemic coronary blood flow due to increased microvascular resistance.
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (6) , e017640
Atypical Left Ventricular Remodeling in Fabry Cardiomyopathy: The Key Diagnostic Role of T1 Mapping
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (6) , e017640
Atypical Left Ventricular Remodeling in Fabry Cardiomyopathy: The Key Diagnostic Role of T1 Mapping
- Open Access
- 7 January 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (1) , e036755
Predictors of Early Death in Patients With Wild‐Type Transthyretin Cardiac Amyloidosis
Background: For the time being, tafamidis is the only approved treatment for wild‐type transthyretin cardiac amyloidosis. However, benefits on all‐cause death only emerge after ≈18 months. The current available staging systems are unable to specifically discriminate patients at high risk of death within 18 months from diagnosis, and the selection of patients who are expected to benefit from tafamidis is left to the clinical judgment of treating physicians, being often based primarily (and sometimes only) on age. We searched baseline variables able to discriminate patients at risk of death within 18 months. Methods and Results: We randomly divided our prospectively maintained database in 2 cohorts, a testing (two thirds) and a validating (one third) set, respectively. We used the Eastern Cooperative Oncology Group–Performance Status as a simple scoring of frailty. We analyzed the clinical, laboratory and instrumental features of 691 consecutive wild‐type transthyretin cardiac amyloidosis patients diagnosed between 2006 and 2021. Median follow‐up was 43 months, and 367 patients (53%) died. Eighteen‐month death was predicted by NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide; cutoff 4200 ng/L), cardiac troponin I (cutoff 92 ng/L), and age (cutoff 80 years). At multivariable analysis, Eastern Cooperative Oncology Group–Performance Status >1 along with the selected variables were independent prognostic determinants and outperformed New York Heart Association functional class. The combination of these variables identified standard‐ and high‐risk patients (all variables above the cutoffs) with a median survival of 57 and 17 months, respectively ( P <0.001). This was confirmed in the validation set. Conclusions: A simple scoring system including age, cardiac biomarkers, and Eastern Cooperative Oncology Group–Performance Status identifies subjects with cardiac wild‐type transthyretin cardiac amyloidosis at high risk of early death.
- 7 January 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (1) , e036755
Open AccessPredictors of Early Death in Patients With Wild‐Type Transthyretin Cardiac Amyloidosis
Background: For the time being, tafamidis is the only approved treatment for wild‐type transthyretin cardiac amyloidosis. However, benefits on all‐cause death only emerge after ≈18 months. The current available staging systems are unable to specifically discriminate patients at high risk of death within 18 months from diagnosis, and the selection of patients who are expected to benefit from tafamidis is left to the clinical judgment of treating physicians, being often based primarily (and sometimes only) on age. We searched baseline variables able to discriminate patients at risk of death within 18 months. Methods and Results: We randomly divided our prospectively maintained database in 2 cohorts, a testing (two thirds) and a validating (one third) set, respectively. We used the Eastern Cooperative Oncology Group–Performance Status as a simple scoring of frailty. We analyzed the clinical, laboratory and instrumental features of 691 consecutive wild‐type transthyretin cardiac amyloidosis patients diagnosed between 2006 and 2021. Median follow‐up was 43 months, and 367 patients (53%) died. Eighteen‐month death was predicted by NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide; cutoff 4200 ng/L), cardiac troponin I (cutoff 92 ng/L), and age (cutoff 80 years). At multivariable analysis, Eastern Cooperative Oncology Group–Performance Status >1 along with the selected variables were independent prognostic determinants and outperformed New York Heart Association functional class. The combination of these variables identified standard‐ and high‐risk patients (all variables above the cutoffs) with a median survival of 57 and 17 months, respectively ( P <0.001). This was confirmed in the validation set. Conclusions: A simple scoring system including age, cardiac biomarkers, and Eastern Cooperative Oncology Group–Performance Status identifies subjects with cardiac wild‐type transthyretin cardiac amyloidosis at high risk of early death.
- 18 May 2024
- Published by Morressier GmbH
Predictors of early mortality in patients with wild-type transthyretin cardiac amyloidosis PC73 (#450)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 18 May 2024
- Published by Morressier GmbH
Predictors of early mortality in patients with wild-type transthyretin cardiac amyloidosis PC73 (#450)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 21 February 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Left atrial dysfunction predicts left ventricular remodelling in patients with preserved ejection fraction after acute ST-elevation myocardial infarction
Andrea Attanasio, Lara Tondi, Serenella Castelvecchio, Vittorio Pazzanese, Anna Palmisano, Antonio Esposito, Pietro Ameri, Claudia Canale, Alberto Cappelletti,
- 21 February 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Left atrial dysfunction predicts left ventricular remodelling in patients with preserved ejection fraction after acute ST-elevation myocardial infarction
Andrea Attanasio, Lara Tondi, Serenella Castelvecchio, Vittorio Pazzanese, Anna Palmisano, Antonio Esposito, Pietro Ameri, Claudia Canale, Alberto Cappelletti,
- Open Access
- 5 February 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (5) , 627-628
Lifestyle intervention on left atrium size and function in patients with metabolic syndrome
Andrea Attanasio, MD, Gianluigi Guida, MD, Giandomenico Disabato, MD, Massimo F Piepoli, MD, PhD, FESC, FHFA; Lifestyle intervention on left atrium size and fun
- 5 February 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (5) , 627-628
Open AccessLifestyle intervention on left atrium size and function in patients with metabolic syndrome
Andrea Attanasio, MD, Gianluigi Guida, MD, Giandomenico Disabato, MD, Massimo F Piepoli, MD, PhD, FESC, FHFA; Lifestyle intervention on left atrium size and fun